Clinical Trial Update: Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 safety study of replication-competent adenovirus Delta-24-RGD (DNX-2401) in patients with recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Delta-24-RGD (DNX-2401) (DNX-2401)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Brain Tumor, Recurring Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED